Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.6M Sell
12,418
-434
-3% -$50.8K 0.34% 70
2026
Q1
$1.55M Sell
12,852
-69
-0.5% -$7.97K 0.37% 60
2025
Q4
$1.36M Sell
12,921
-17
-0.1% -$1.6K 0.33% 68
2025
Q3
$1.09M Buy
12,938
+106
+0.8% +$8.73K 0.28% 73
2025
Q2
$1.02M Sell
12,832
-228
-2% -$18.1K 0.29% 73
2025
Q1
$1.17M Buy
13,060
+793
+6% +$74K 0.42% 60
2024
Q4
$1.22M Sell
12,267
-226
-2% -$23.3K 0.43% 59
2024
Q3
$1.42M Sell
12,493
-1,072
-8% -$127K 0.5% 51
2024
Q2
$1.68M Buy
13,565
+1,559
+13% +$201K 0.64% 43
2024
Q1
$1.58M Buy
12,006
+705
+6% +$86.9K 0.64% 43
2023
Q4
$1.23M Sell
11,301
-293
-3% -$30.4K 0.56% 47
2023
Q3
$1.19M Buy
11,594
+749
+7% +$80.7K 0.62% 43
2023
Q2
$1.25M Sell
10,845
-1,399
-11% -$159K 0.65% 41
2023
Q1
$1.3M Buy
12,244
+2,226
+22% +$240K 0.72% 37
2022
Q4
$1.11M Sell
10,018
-24
-0.2% -$2.45K 0.66% 38
2022
Q3
$864K Sell
10,042
-201
-2% -$17.9K 0.58% 41
2022
Q2
$934K Sell
10,243
-2,062
-17% -$183K 0.6% 38
2022
Q1
$1.01M Buy
12,305
+746
+6% +$58.8K 0.55% 42
2021
Q4
$886K Buy
+11,559
New +$921K 0.46% 45

Other funds holding MRK

Bill Few Associates's MRK Position: Q2 2026 in Review

Bill Few Associates reduced its Merck (MRK) stake by 3.4% in Q2 2026, selling an estimated $50.8K and leaving 12,418 shares worth $1.6M. The position accounts for 0.34% of the portfolio, ranked #70.

Bill Few Associates first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.68M in Q2 2024. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Bill Few Associates held 12,418 shares of Merck worth $1.6M as of Q2 2026.
  • Bill Few Associates sold 434 Merck shares in Q2 2026, an estimated $50.8K.
  • Merck made up 0.34% of Bill Few Associates's portfolio in Q2 2026, its #70 holding.
  • Bill Few Associates first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
  • Bill Few Associates's Merck position peaked at $1.68M in Q2 2024.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Bill Few Associates's 13F filing for Q2 2026, filed 7 Jul 2026.